Key result
Various strategies to achieve amplification of ACE2 activity, including soluble recombinant ACE2 protein and novel shorter ACE2 variants, offer potential therapeutic benefits.
Why the study?
Targeting Ang II has been key for three decades, but the therapeutic potential of amplifying ACE2 activity to degrade Ang II to organ-protective Ang-(1-7) warrants review.
Amplification of ACE2 activity through recombinant proteins or novel variants represents a potential therapeutic strategy for diseases involving the renin-angiotensin system and SARS-CoV-2.
May support ACE2 as therapeutic target for organ protection; leaves open confirmation in prospective trials.
The renin angiotensin system (RAS) plays an important role in the pathogenesis of variety of diseases. Targeting the formation and action of angiotensin II (Ang II), the main RAS peptide, has been the key therapeutic target for last three decades. ACE-related carboxypeptidase (ACE2), a monocarboxypeptidase that had been discovered 20 years ago, is one of the catalytically most potent enzymes known to degrade Ang II to Ang-(1-7), a peptide that is increasingly accepted to have organ-protective properties that oppose and counterbalance those of Ang II. In addition to its role as a RAS enzyme ACE2 is the main receptor for SARS-CoV-2. In this review, we discuss various strategies that have been used to achieve amplification of ACE2 activity including the potential therapeutic potential of soluble recombinant ACE2 protein and novel shorter ACE2 variants.
No takes yet. Share an insight, caveat, or question.
Márquez et al. (2020) conducted a review in RAS-related diseases and SARS-CoV-2. ACE2 amplification strategies was evaluated. Various strategies to achieve amplification of ACE2 activity, including soluble recombinant ACE2 protein and novel shorter ACE2 variants, offer potential therapeutic benefits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Acta Physiologica